All times shown are EST.
7:20 am Breakfast & Registration Opens
8:20 am Chair’s Opening Remarks
DELVING INTO THE EVOLUTION OF PARP & ATR IN THE PAST YEAR: A REVIEW OF PARP AS MORE AGENTS ARE APPROVED & A DEEP DIVE INTO ATR POTENTIAL & PROGRESSION
8:30 am Laying Out The Current DDRi Landscape and Analysing Future Directions
Synopsis
- Reflecting on where we’re at right now: an overview of the current DDR landscape
- A focus on 2nd generation targets: working towards an approval?
- Evaluating future directions: 2023 and beyond
9:00 am Exploring a Novel Dual PARP-HDAC Inhibitor for the Treatment of Ewing Sarcoma
Synopsis
- kt-3000 series compounds exhibit dual PARP1/2 and HDAC inhibitor activity
- Co-inhibition of PARP1/2 and HDACs amplifies DNA damage and cytotoxicity
- Ewing sarcoma cells are highly sensitive to combined PARP and HDAC inhibition
9:30 am ATR: The Target of The Year – How Has this Target Progressed in 2022 & What Are the Current Challenges Faced Clinically
Synopsis
- EMD Serono unveiled its new oral ATR inhibitor (M1774) with best-in-class potential
- The search for BM-defined populations sufficient to support monotherapy registration continues
- While there have been setbacks for chemotherapy-ATRi combinations, combinations with ICI look increasingly promising
10:00 am Speed Networking
Synopsis
A session dedicated to taking advantage of face-to-face networking time. An exciting opportunity to get an understanding of who else is overcoming similar challenges within the DDR space.
11:00 am Exploring drug polypharmacology across kinases and PARPs in live cells with NanoBRET probes
Synopsis
- Applications of NanoBRET for targets in synthetic lethality pathways
- Characterizing novel interactions for DDR kinase inhibitors in cells
- Mechanistic analysis of target engagement across the PARP enzyme family
ANALYZING HOW INHIBITION OF THE DDR PATHWAY AFFECTS THE IMMUNE MICROENVIRONMENT
11:15 am Combining Inhibitors of the DNA Damage Response Pathway with Immunotherapies to Treat Cancer
Synopsis
- The multiple interfaces between the DDR and the immune response
- PARP inhibitor immune priming in BRCA deficient cancers
- The link between ATR inhibition, replication stress and the ability to overcome immunotherapy resistance
11:45 am Effects of Polymerase Theta Inhibition On the DDR-Deficient Immune Microenvironment
Synopsis
- What pathways drive immune cell infiltration following polymerase theta inhibition?
- Is an immune response required for maximal efficacy of polymerase theta inhibitors?
- How can polymerase theta-induced immune responses be augmented further to improve anti-tumor efficacy?
12:15 pm Panel Discussion: DDR Inhibitors & the Immune Response Interface
Synopsis
- DNA damage checkpoint activation, inducing the expression of antimicrobial peptides and activating immune cell receptor ligands: what are the ways DDRis impact these immune responses
- Which pathways within DDR are involved in immune signalling?
- DNA damage and chronic inflammation: what is the link?
12:45 pm Lunch & Networking
ADDRESSING RESISTANCE WITH NEXT GENERATION TARGETS: DRUG DEVELOPMENT & CLINICAL TRIALS OF FAMILIAR TARGETS
Chair By:
1:45 pm Reviewing the Renaissance of WEE1 Inhibitors; an Old Target with a Lot of New Potential
Synopsis
- The uprise of WEE1 inhibitor and its impacts
- Designing of WEE1 inhibitors
- Recent WEE1 inhibitor clinical data
2:25 pm Next Generation DDR/Synthetic Lethality Targets: Mining DNA Metabolism for Gold
Synopsis
- Approaches to drug discovery
- Overview of Polymerase theta as a tumour selective drug target
- Exploiting cancer replication stress: spotlight on WRN helicase
LOOKING TO THE FUTURE & NEXT GENERATION TARGETS: EXPLORING NOVEL TARGETS ON THE HORIZON & DISCUSSING THEIR POTENTIAL AS MONOTHERAPY AGENTS
2:45 pm Exploiting Vulnerabilities in Cancer with Next Generation DDR Inhibitors Targeting Cyclin K or PARG
Synopsis
- Cyclin K degrading molecular glues potentially target CDK12/13-driven expression of DDR genes
- PARG inhibitors may target homologous recombination deficiencies in cancer in a complementary and differentiated way than PARP inhibitors
- Targeting Cyclin K or PARG may provide opportunities to inhibit DDR pathways that leverage contextual vulnerabilities in cancer, including CDK12-amplified cancers and PARPi-resistant HRD-positive cancers
3:15 pm Afternoon Break & Networking
3:45 pm Exploiting DNA Repair Defects via Direct DNA Modification – A New Paradigm in Oncology Drug Development
Synopsis
- Overview of DNA modifiers (DMs) and how they can be engineered to exploit DDR defects
- Strategies to evade known drug resistance pathways using DMs
- Potential for combination therapies with DMs
4:15 pm Panel Discussion: How Are Newer Targets Being Validated to Move Towards Clinical Trials?
Synopsis
- What is the rationale behind selecting novel targets for research?
- How do these targets differ from previous projects?
- What do these new targets offer to existing drug development projects?
4:45 pm Chair’s Closing Remarks
4:50 pm Scientific Poster Session
Synopsis
After the formal presentations have finished for the afternoon, the learning and networking carries on. The Poster Session allows you to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships. During this session, scientific posters will be presented on the latest advancements in the DDR field.